76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Corcept Therapeutics Inc
Closed
SectorHealthcare
70.13 -1.48
Overview
Share price change
24h
Min
69.73
Max
70.64
Income | -9.8M 21M |
|---|---|
Sales | -25M 157M |
P/E Sector Avg | 61.365 51.748 |
EPS | 0.169 |
Profit margin | 13.069 |
Employees | 500 |
EBITDA | -22M 3.4M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +98.87% upside |
Next Earnings | 28 Jul 2025 |
|---|
Market Cap | -229M 7.5B |
|---|---|
Previous open | 71.61 |
Previous close | 70.13 |
Corcept Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Corcept Therapeutics Inc Forecast
Price Target
By TipRanks
98.87% upside
12 Months Forecast
Average 139.33 USD 98.87%
High 145 USD
Low 131 USD
Based on 4 Wall Street analysts offering 12 month price targets forCorcept Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
